News & Press
The Access to Comprehensive Genomic Profiling Coalition Welcomes Blueprint Medicines as a Member
WASHINGTON, April 15, 2022 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Blueprint Medicines to its coalition of companies advocating for coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer by U.S. health insurers.
The Access to Comprehensive Genomic Profiling Coalition Welcomes Strata Oncology as a Member
WASHINGTON, July 12, 2021 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Strata Oncology, a precision oncology company advancing molecular indications for cancer therapies. ACGP is comprised of diagnostics companies, laboratory service providers, and CGP industry stakeholders to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.
The Access to Comprehensive Genomic Profiling Coalition Welcomes Two New Members – PGDx and Sema4
WASHINGTON, June 23, 2021 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Personal Genome Diagnostics (PGDx), a leader in cancer genomics, and Sema4, a patient-centered health intelligence company, to its coalition of diagnostics companies, laboratory service providers, and CGP industry stakeholders to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.
The Access to Comprehensive Genomic Profiling Coalition Adds New Member
WASHINGTON, May 20, 2021 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of Mayo Clinic Laboratories to its coalition of diagnostics companies and laboratory service providers to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.
Members of Access to Comprehensive Genomic Profiling (ACGP) Participated in Precision Medicine Leadership Summit’s Virtual Series on Genomics and Precision Medicine
On April 27, 2021, members of the Access to Comprehensive Genomic Profiling (ACGP) participated in the Precision Medicine Leadership Summit’s Virtual Series on Genomics and Precision Medicine. Lauren Feldman, Vice President, Value, Access & Pricing at ADVI, moderated the panel “Comprehensive Genomic Profiling: A New Standard of Care in Oncology”, which covered:
- The landscape for comprehensive genomic profiling
- The obstacles to coverage & reimbursement
- Access to Comprehensive Genomic Profiling Coalition
The panelists were as follows: Mina Alsaraf Allo, PharmD, MPH, VP, Commercial Markets – East, Tempus, Trish Brown, MS, Director, AMR Payer Partner, Field Market Access Lead, Illumina, and Rob Dumanois, Director, Reimbursement Strategy, Thermo Fisher Scientific.
Access to Comprehensive Genomic Profiling (ACGP) is a collaborative coalition of leading molecular diagnostics companies and laboratories that aims to raise awareness about comprehensive genomic profiling (CGP) for advanced cancer patients. For more information, please visit: https://accesstocgp.com/
AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation Join the Access to Comprehensive Genomic Profiling Coalition
WASHINGTON, April 19, 2021 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation (NYSE: NVTA) to its coalition of companies advocating for appropriate coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer by U.S. health insurers.